

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



Product Information

ApoA1 Blocking Peptide

Item No. 13079

ApoA1 is a major protein component in high-density lipoproteins (HDLs). It acts as an acceptor for sequential transfers of phospholipids and free cholesterol from peripheral tissues and transports cholesterol to the liver and other tissues for excretion and steroidogenesis. Serum ApoA1 levels are inversely related to the risk of developing atherosclerosis. Lossof-function mutations are causes of diseases such as HDL deficiency type 1 (or Tangier disease) and type 2 (familial hypoalphalipoproteinemia), and systemic non-neuropathic amyloidosis.^{3,4} ApoA1 is comprised of a single polypeptide chain of 243 amino acids residues with an estimated molecular weight of 28 kDa. Cayman's ApoA1 Polyclonal Antibody (Item No. 10008463) detects the protein by western blot analysis in tissue/cell samples such as liver, intestine, and HepG2

Laboratory Procedures

This vial contains 200 µg peptide in 200 µl TBS, pH 7.4, containing 0.1% BSA and 0.02% sodium azide. The ApoA1 blocking peptide can be used in conjunction with Cayman's ApoA1 Polyclonal Antibody (Item No. 10008463) to block protein-antibody complex formation during immunochemical analysis of ApoA1.

Store this peptide solution at -20°C. It will be stable for at least two years. To block antibody/protein complex formation, the following procedure is recommended:

- 1. Mix the ApoA1 Polyclonal Antibody (Item No. 10008463) and blocking peptide together in a 1:1 (v/v) ratio in a microfuge tube. For example, mix 50 µl of antibody and 50 µl of peptide.*
- 2. Incubate for one hour at room temperature with occasional mixing prior to further dilution and application of the mixture to the immunoblot.
- 3. Dilute the mixture to the final working antibody concentration and apply to the slide or membrane as usual. *This is a recommended mixture. The minimum amount of peptide needed for complete blocking has not been precisely determined and may vary depending on the sample being analyzed. The amount of peptide required may need to be increased if sufficient blocking does not occur.

References

- Ajees, A.A., Anantharamaiah, G.M., Mishra, V.K., et al. Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases. Proc. Natl. Acad. Sci. USA 103(7), 2126-2131 (2006).
- Haas, M.J., Reinacher, D., Li, J.P., et al. Regulation of ApoAI gene expression with acidosis: Requirement for a transcriptional repressor. J. Mol. Endocrinol. 27, 43-57 (2001).
- Tall, A.R. and Wang, N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J. Clin. Invest. 106(10), 1205-1207 (2000).
- Cheung, M.C., Mendez, A.J., Wolf, A.C., et al. Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling tangier disease and their effects on intracellular cholesterol efflux. J. Clin. Invest. 91, 522-529 (1993).

Related Products

For a list of related products please visit: www.caymanchem.com/catalog/13079

WARNING: This product is for laboratory research only: not for administration to humans. Not for human or veterinary DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman **warrants only** to the original customer that the material will <u>meet our specifications</u>

at the time of delivery.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have any obligation or liability, whether in tort (including negligence) or in contract, for any direct, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitity does not apply in the case of intentional acts or negligence of Cayman, is directors or its employees.

Buyer's exclusive remedy and Cayman's sole liability hereunder shall be limited to a refund of the purchase price, or at Cayman's option, the replacement, at no cost to Buyer, of all material that

Buyers exclusive remedy and Caymans sole hability increments man be immed to a teams of the purchase of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

Copyright Cayman Chemical Company, 10/29/2013

Cayman Chemical

Mailing address

1180 E. Ellsworth Road Ann Arbor, MI 48108 USA

Phone

(800) 364-9897 (734) 971-3335

(734) 971-3640

custserv@caymanchem.com

www.caymanchem.com